Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.

被引：0

作者：

Rha, Sun Young

Lee, Jeeyun

Ryu, Min-Hee

Yin, Lina

Leconte, Pierre

Bhagia, Pooja

Oh, Do-Youn

机构：

[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol,Yonsei Canc Ctr, Seoul, South Korea

[2] Samsung Med Ctr, Seoul, South Korea

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[4] Merck & Co Inc, Rahway, NJ USA

[5] MSD France, Puteaux La Defense, France

[6] Seoul Natl Univ, Coll Med, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.428

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：428 / 428

页数：1

共 50 条

[31] RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma [J].

Xu, R. ;

Arkenau, T. ;

Bang, Y. ;

Denlinger, C. ;

Kato, K. ;

Tabernero, J. ;

Wang, J. ;

Li, J. ;

Castro, H. ;

Moehler, M. .

ANNALS OF ONCOLOGY, 2020, 31 :S97-S98

[32] First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study [J].

Qin, Shukui ;

Bai, Yuxian ;

Li, Jin ;

Pan, Hongming ;

Luo, Suxia ;

Qu, Yanli ;

Ye, Feng ;

Yang, Lin ;

Liu, Tianshu ;

Li, Wei ;

Chen, Xi ;

Yang, Jianwei ;

Ying, Jieer ;

Lin, Xiaoyan ;

Zhao, Lin ;

Liang, Xinjun ;

Mao, Yixiang ;

Guo, Run ;

Zuo, Yi ;

Bordia, Sonal ;

Li, Shouguo .

ADVANCES IN THERAPY, 2025, 42 (04) :1892-1906

[33] Phase III KEYNOTE-585 study of chemotherapy (Chemo) plus pembrolizumab (Pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer [J].

Bang, Y-J. ;

Van Cutsem, E. ;

Fuchs, C. S. ;

Ohtsu, A. ;

Tabernero, J. ;

Ilson, D. H. ;

Hyung, W. J. ;

Strong, V. E. ;

Goetze, T. O. ;

Yoshikawa, T. ;

Tang, L. H. ;

Hwang, P. M. T. ;

Adelberg, D. ;

Shitara, K. .

ANNALS OF ONCOLOGY, 2018, 29 :268-268

[34] The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma [J].

Rha, S. Y. ;

Kawazoe, A. ;

Bai, Y. ;

Xu, J. ;

Lonardi, S. ;

Metges, J-P. ;

Yanez Weber, P. E. ;

Wyrwicz, L. S. ;

Shen, L. ;

Ostapenko, Y. V. ;

Bilici, M. ;

Chung, H. C. ;

Shitara, K. ;

Qin, S. ;

van Cutsem, E. ;

Tabernero, J. ;

Li, K. ;

Shih, C-S. ;

Bhagia, P. ;

Janjigian, Y. Y. .

ANNALS OF ONCOLOGY, 2023, 34 :S1521-S1522

[35] KEYNOTE-585: Phase 3 study of chemotherapy (chemo) plus pembrolizumab (pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer. [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Fuchs, Charles S. ;

Ohtsu, Atsushi ;

Tabernero, Josep ;

Ilson, David H. ;

Hyung, Woo Jin ;

Strong, Vivian E. ;

Goetze, Thorsten Oliver ;

Yoshikawa, Takaki ;

Tang, Laura H. ;

Hwang, Peggy May Tan ;

Shitara, Kohei .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[36] Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis [J].

Zhu, Youwen ;

Liu, Kun ;

Zhu, Hong ;

Wu, Haijun .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16

[37] Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. [J].

Janjigian, Yelena Y. ;

Kawazoe, Akihito ;

Yanez, Patricio Eduardo ;

Luo, Suxia ;

Lonardi, Sara ;

Kolesnik, Oleksii ;

Barajas, Olga ;

Bai, Yuxian ;

Shen, Lin ;

Tang, Yong ;

Wyrwicz, Lucjan ;

Shitara, Kohei ;

Qin, Shukui ;

Van Cutsem, Eric ;

Tabernero, Josep ;

Li, Lie ;

Shih, Chie-Schin ;

Bhagia, Pooja ;

Chung, Hyun Cheol Cheol .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[38] A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. [J].

Xu, Rui-hua ;

Arkenau, Hendrik-Tobias ;

Bang, Yung-Jue ;

Denlinger, Crystal S. ;

Kato, Ken ;

Tabernero, Josep ;

Wang, Jin ;

Li, Jiang ;

Castro, Henry ;

Moehler, Markus Hermann .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[39] Nivolumab plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer-regional differences in efficacy [J].

Mehta, Rutika ;

Shah, Manish A. .

ANNALS OF PALLIATIVE MEDICINE, 2022,

[40] A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ) [J].

Li, Z. ;

Ji, J. ;

Bu, Z. ;

Wang, Y. ;

Wu, Z. ;

Nie, P. ;

Li, W-L. ;

Li, C. ;

You, J. ;

Hu, W. ;

Zhang, Y. ;

Chen, L. ;

Zhao, P. ;

Li, G. ;

Li, Y. ;

Zhuang, J. ;

Shen, J. ;

Feng, D. ;

Fang, J. .

ANNALS OF ONCOLOGY, 2024, 35 :S911-S911

← 1 2 3 4 5 →